The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ABLE: Phase 2, single-arm, two-stage study of nabpaclitaxel with anti-PD1/PDL1 in advanced urothelial cancer.
 
Irene Tsung
No Relationships to Disclose
 
Edward Green
No Relationships to Disclose
 
Phillip Lee Palmbos
Research Funding - Immunomedics; Roche
 
Zachery R Reichert
Consulting or Advisory Role - Dendreon
Research Funding - AstraZeneca (Inst)
 
Ulka N. Vaishampayan
Consulting or Advisory Role - Advanced Accelerator Applications; Alkermes; Bayer; Bristol-Myers Squibb/Medarex; Exelixis; Helsinn Therapeutics; Merck Serono; Pfizer
Speakers' Bureau - Bayer; Exelixis; Pfizer
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Merck KGaA
 
David C. Smith
Research Funding - Agensys (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb/Medarex (Inst); ESSA (Inst); Genentech (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Roche (Inst); Seagen (Inst)
 
Megan Veresh Caram
No Relationships to Disclose
 
Sarah Elizabeth Yentz
No Relationships to Disclose
 
Stephanie Daignault-Newton
Other Relationship - American Urological Association
 
Zachery Sloan
No Relationships to Disclose
 
Laura Hurley
No Relationships to Disclose
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; BMS; Merck; Pfizer
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Harpoon Therapeutics (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Progenics (Inst); Progenics (Inst); Prometheus (Inst); Roche (Inst)
Travel, Accommodations, Expenses - BMS; Merck